Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?
about
Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancerPotential implication of the chemical properties and bioactivity of nitrone spin traps for therapeuticsStructural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acidFirst-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumorsBiological evaluation of new largazole analogues: alteration of macrocyclic scaffold with click chemistry.Superoxide radical anion adduct of 5,5-dimethyl-1-pyrroline N-oxide. 6. Redox propertiesPotent and orally efficacious bisthiazole-based histone deacetylase inhibitorsInhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancerSynthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors.Nonhistone protein acetylation as cancer therapy targets.Regulation of immune responses by histone deacetylase inhibitorsPhase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.Residues in the 11 A channel of histone deacetylase 1 promote catalytic activity: implications for designing isoform-selective histone deacetylase inhibitors.Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffoldTargeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?Histone deacetylase inhibitors as novel anticancer therapeutics.The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process.Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells.Multiple roles of class I HDACs in proliferation, differentiation, and development.HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.Histone deacetylases in kidney development: implications for disease and therapy.Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy.Amidation inhibitors 4-phenyl-3-butenoic acid and 5-(acetylamino)-4-oxo-6-phenyl-2-hexenoic acid methyl ester are novel HDAC inhibitors with anti-tumorigenic properties.Systems approach to the pharmacological actions of HDAC inhibitors reveals EP300 activities and convergent mechanisms of regulation in diabetes.Potent and selective HDAC6 inhibitory activity of N-(4-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes as novel sulfur analogues of Tubastatin A.Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytesDesign, Synthesis, and Biological Evaluation of 2-Aminobenzanilide Derivatives as Potent and Selective HDAC Inhibitors
P2860
Q24310439-401273BB-D657-4A08-A4EE-051BEFC6A908Q28818673-66051448-7729-47ED-9C9F-EEEE6ADA44C5Q33274378-4BF1B8FB-1F7C-43C0-B9BD-557D4B145418Q33410544-3F4BE3D5-0FF7-4A1C-9895-034827E2B821Q33636013-84A6D993-6E35-49F5-94F1-BB99EF235463Q33638807-562B0C1A-F687-4967-812B-9AD6F1448075Q33768549-C8FADFCD-2135-4BB0-B639-50E8392B99A5Q33831971-79C8EF61-4CF9-4EE8-9ACE-34BB0DF516A0Q33844751-A0DFB678-9906-4E89-A2BF-62A83E81A144Q34318452-D67F77D5-996A-496F-A7B0-B28E266799E1Q35637328-BDD82982-9801-4048-8FF6-D6F778C68196Q35739676-B40CD9A6-27BD-4A39-9B04-CA7ACCE027D3Q35855571-CA18FF89-008B-4CFB-886F-37DFD9F0D128Q36408642-3FF8B484-ABE9-4FEB-8DBF-2D489D11C050Q36802594-5809E77E-8E85-479F-99ED-E80A8F75ADEFQ36995044-02774416-5584-4FFC-99CA-000976FEC14CQ37170927-65744D1E-5817-45CD-B3FD-3BBA044606C8Q37317209-5EEE50A5-9860-476F-A1A1-DDD3B67EAF56Q37325492-F4A92EBE-B485-4D5B-B4F5-36BF5BD4AB83Q37346960-41D500BD-1F3F-4AAF-804F-BCEB898EA74CQ37420201-F5CDF18C-678A-4C45-BFE2-7988DB678C36Q37621254-ABF13242-F185-4060-AA87-EF201A97E60FQ37979639-4ACC3CA5-A936-4AB9-94AE-192481086F19Q37993586-49621EBE-71D9-43F6-BBF4-04380E72185FQ38020758-29F61CBB-5A71-4FCF-9B1B-07DA72826EC9Q38204487-0718F1C2-81D9-409B-AFD6-04A80BCE032DQ38865033-ABF974E8-685F-468A-AF2C-D834EB861EFCQ48666421-2D38B2D6-50B1-4470-B17F-BBDB021CC081Q49131145-6E3DD7D5-3934-4B5F-BA59-4D275591A331Q50862788-536858D6-5681-4FA8-BE29-49B919113196Q58049799-5B74879F-837E-4103-B5DA-C7C400DE0859Q58862225-E2767374-1149-4B23-B22F-6B8630DA477E
P2860
Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Will broad-spectrum histone de ...... ed by more specific compounds?
@ast
Will broad-spectrum histone de ...... ed by more specific compounds?
@en
type
label
Will broad-spectrum histone de ...... ed by more specific compounds?
@ast
Will broad-spectrum histone de ...... ed by more specific compounds?
@en
prefLabel
Will broad-spectrum histone de ...... ed by more specific compounds?
@ast
Will broad-spectrum histone de ...... ed by more specific compounds?
@en
P2860
P356
P1433
P1476
Will broad-spectrum histone de ...... ed by more specific compounds?
@en
P2093
Karagiannis TC
P2860
P2888
P356
10.1038/SJ.LEU.2404464
P577
2006-11-16T00:00:00Z